Achilles Therapeutics plc

NasdaqCM:ACHL Rapporto sulle azioni

Cap. di mercato: US$44.0m

Achilles Therapeutics Gestione

Gestione criteri di controllo 2/4

Achilles Therapeutics Il CEO è Iraj Ali, nominato in Jan2018, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 1.70M, composta da 27.3% di stipendio e 72.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.71% delle azioni della società, per un valore di $ 1.19M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.4 anni e 4.5 anni.

Informazioni chiave

Iraj Ali

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO27.3%
Mandato del CEO6.8yrs
Proprietà del CEO2.7%
Durata media del management5.4yrs
Durata media del Consiglio di amministrazione4.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Iraj Ali rispetto agli utili di Achilles Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$463k

-US$70m

Compensazione vs Mercato: La retribuzione totale di Iraj ($USD 1.70M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 646.00K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Iraj con le performance aziendali.


AMMINISTRATORE DELEGATO

Iraj Ali (49 yo)

6.8yrs

Mandato

US$1,698,000

Compensazione

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Iraj Ali
CEO & Director6.8yrsUS$1.70m2.71%
$ 1.2m
Sergio Quezada
Founder & Chief Scientific Officer8.8yrsNessun dato1.12%
$ 494.9k
Robert Coutts
Chief Financial Officer4yrsNessun dato0.66%
$ 288.9k
Mark Lowdell
Founder & Member of Scientific Advisory Board8.8yrsNessun datoNessun dato
Charles Swanton
Founder & Member of Scientific Advisory Board8.8yrsNessun datoNessun dato
Lee Stern
Vice President of Investor Relations & External Communications3.9yrsNessun datoNessun dato
Daniel Carey Hood
General Counsel & Company Secretary2yrsNessun datoNessun dato
Julia Wilson
Head of Communicationsno dataNessun datoNessun dato
Tariq Ahmed
Executive Vice President of Peopleno dataNessun datoNessun dato
Edward Samuel
Executive Vice President of Technical Operationsno dataNessun datoNessun dato
Shree Patel
Executive Vice President of Supply Operationsno dataNessun datoNessun dato
James A. Taylor
Chief Business Officer2.8yrsNessun datoNessun dato

5.4yrs

Durata media

50.5yo

Età media

Gestione esperta: Il team dirigenziale di ACHL è esperto e expertise (durata media dell'incarico 5.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Iraj Ali
CEO & Director8.7yrsUS$1.70m2.71%
$ 1.2m
Mark Lowdell
Founder & Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Charles Swanton
Founder & Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Edwin Moses
Independent Chairman of the Board5.9yrsUS$379.00k0.55%
$ 242.4k
Carsten Boess
Independent Non-Executive Director4.6yrsUS$176.00k0%
$ 0
Markwin Velders
Member of Scientific Advisory Board3.5yrsNessun datoNessun dato
Scott Antonia
Member of Scientific Advisory Board4.5yrsNessun datoNessun dato
Michael Giordano
Independent Non-Executive Director6.2yrsUS$189.00k0.11%
$ 50.0k
Karl Peggs
Founder & Member of Scientific Advisory Boardless than a yearNessun dato1.36%
$ 600.2k
Elizabeth Jaffee
Member of Scientific Advisory Board4.5yrsNessun datoNessun dato
Christopher Klebanoff
Member of Scientific Advisory Board4.5yrsNessun datoNessun dato
Alena Gros
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato

4.5yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ACHL sono considerati esperti (durata media dell'incarico 4.5 anni).